Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats
The aim of the present research was to describe the consequences of hyperlipidemia (HL) on the pharmacokinetics of glibenclamide (Gb) in poloxamer 407-induced hyperlipidemic rats. Rats were given intraperitoneal dose of poloxamer 407 to cause hyperlipidemia. A single oral dose of Gb (10 mg/Kg) was g...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-07-01
|
| Series: | Saudi Pharmaceutical Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016421000992 |
| _version_ | 1819070649932447744 |
|---|---|
| author | Yousef A. Bin Jardan Abdul Ahad Mohammad Raish Ajaz Ahmad Mohd Aftab Alam Abdullah M. Al-Mohizea Fahad I. Al-Jenoobi |
| author_facet | Yousef A. Bin Jardan Abdul Ahad Mohammad Raish Ajaz Ahmad Mohd Aftab Alam Abdullah M. Al-Mohizea Fahad I. Al-Jenoobi |
| author_sort | Yousef A. Bin Jardan |
| collection | DOAJ |
| description | The aim of the present research was to describe the consequences of hyperlipidemia (HL) on the pharmacokinetics of glibenclamide (Gb) in poloxamer 407-induced hyperlipidemic rats. Rats were given intraperitoneal dose of poloxamer 407 to cause hyperlipidemia. A single oral dose of Gb (10 mg/Kg) was given to normal and HL rats. The Cmax and tmax after oral dose of Gb in normal rats were 340.10 µg/ml and 3.67 h, respectively. Whereas, the Cmax and tmax after oral dose of Gb in HL rats were noted as 773.39 µg/ml and 2.50 h respectively. The AUC value of Gb was found considerably higher in the HL rats. While the plasma clearance (CL) after oral dose of Gb was 2.53 ml/h and 1.39 ml/h in normal and HL rats respectively. The improved plasma concentration of Gb following oral dosing in rats with HL seems to be due to a direct influence on hepatic clearance or metabolizing enzymes. In conclusion, the Gb pharmacokinetics was considerably affected by the HL in rats. Such findings play an important role for predicting the alterations in the pharmacokinetics of drugs including GB, in cases having hyperlipidemia. |
| first_indexed | 2024-12-21T17:09:18Z |
| format | Article |
| id | doaj.art-d315de12bd3546d7898e92cd53da633c |
| institution | Directory Open Access Journal |
| issn | 1319-0164 |
| language | English |
| last_indexed | 2024-12-21T17:09:18Z |
| publishDate | 2021-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Saudi Pharmaceutical Journal |
| spelling | doaj.art-d315de12bd3546d7898e92cd53da633c2022-12-21T18:56:27ZengElsevierSaudi Pharmaceutical Journal1319-01642021-07-01297719723Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic ratsYousef A. Bin Jardan0Abdul Ahad1Mohammad Raish2Ajaz Ahmad3Mohd Aftab Alam4Abdullah M. Al-Mohizea5Fahad I. Al-Jenoobi6Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; Corresponding author.Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaThe aim of the present research was to describe the consequences of hyperlipidemia (HL) on the pharmacokinetics of glibenclamide (Gb) in poloxamer 407-induced hyperlipidemic rats. Rats were given intraperitoneal dose of poloxamer 407 to cause hyperlipidemia. A single oral dose of Gb (10 mg/Kg) was given to normal and HL rats. The Cmax and tmax after oral dose of Gb in normal rats were 340.10 µg/ml and 3.67 h, respectively. Whereas, the Cmax and tmax after oral dose of Gb in HL rats were noted as 773.39 µg/ml and 2.50 h respectively. The AUC value of Gb was found considerably higher in the HL rats. While the plasma clearance (CL) after oral dose of Gb was 2.53 ml/h and 1.39 ml/h in normal and HL rats respectively. The improved plasma concentration of Gb following oral dosing in rats with HL seems to be due to a direct influence on hepatic clearance or metabolizing enzymes. In conclusion, the Gb pharmacokinetics was considerably affected by the HL in rats. Such findings play an important role for predicting the alterations in the pharmacokinetics of drugs including GB, in cases having hyperlipidemia.http://www.sciencedirect.com/science/article/pii/S1319016421000992DiabetesGlyburideHyperlipidemiaLipoproteinsRats |
| spellingShingle | Yousef A. Bin Jardan Abdul Ahad Mohammad Raish Ajaz Ahmad Mohd Aftab Alam Abdullah M. Al-Mohizea Fahad I. Al-Jenoobi Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats Saudi Pharmaceutical Journal Diabetes Glyburide Hyperlipidemia Lipoproteins Rats |
| title | Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats |
| title_full | Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats |
| title_fullStr | Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats |
| title_full_unstemmed | Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats |
| title_short | Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats |
| title_sort | assessment of glibenclamide pharmacokinetics in poloxamer 407 induced hyperlipidemic rats |
| topic | Diabetes Glyburide Hyperlipidemia Lipoproteins Rats |
| url | http://www.sciencedirect.com/science/article/pii/S1319016421000992 |
| work_keys_str_mv | AT yousefabinjardan assessmentofglibenclamidepharmacokineticsinpoloxamer407inducedhyperlipidemicrats AT abdulahad assessmentofglibenclamidepharmacokineticsinpoloxamer407inducedhyperlipidemicrats AT mohammadraish assessmentofglibenclamidepharmacokineticsinpoloxamer407inducedhyperlipidemicrats AT ajazahmad assessmentofglibenclamidepharmacokineticsinpoloxamer407inducedhyperlipidemicrats AT mohdaftabalam assessmentofglibenclamidepharmacokineticsinpoloxamer407inducedhyperlipidemicrats AT abdullahmalmohizea assessmentofglibenclamidepharmacokineticsinpoloxamer407inducedhyperlipidemicrats AT fahadialjenoobi assessmentofglibenclamidepharmacokineticsinpoloxamer407inducedhyperlipidemicrats |